Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc ONCY


Primary Symbol: T.ONC

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Quentin30on Dec 13, 2022 1:17pm
102 Views
Post# 35168901

RE:RE:Takeda acquiring Nimbus Therapeutics subsid for US$4 Billion

RE:RE:Takeda acquiring Nimbus Therapeutics subsid for US$4 BillionYou can use Pela with coconut milk too Noteable, but to administer it to patients and make money from sales, you do realise you need a marketing authorisation, you do realise that right ?

So, for all the combos you mention, all of which will require (for US at least) two randomised trials... WHO will be paying for all that..? It seems all ONCY ever does is start yet more trials, never quite having enough data to prove if it's worth pursuing or not... clever strategy...

LOL...

Phase II mBC trial started in 2012, so to get us through Phase III and to Approval will have taken 14 years (that's of course if we'd started this summer... ) so now its more like 15 years...

The first Crispr CAS-9 dossier is on a rolling submission already with FDA. It could be approved by end of Q2 2023... and that will just open the floodgates... Like I say, time is ticking...
<< Previous
Bullboard Posts
Next >>